In The News Posted March 6, 2019 Share Posted March 6, 2019 LUND, Sweden, March 6, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that Søren Tulstrup, President and CEO of Hansa Biopharma, will present at the Cowen 39th Annual Health ... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.